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ABSTRACT
OBJECTIVE: To analyze whether lawsuits for medicines filed against the state of Rio Grande 
do Norte agree with medical-sanitary and pharmaceutical assistance management criteria 
established by the public policies of access to medicines in force in Brazil.
METHODS: This is a descriptive and retrospective study of the individual lawsuits that claimed 
medicines in the state of Rio Grande do Norte between 2013 and 2017. Information was collected 
from the procedural documents on the requested medicines, the diagnoses referred and the 
origin of the medical prescription, in order to analyze medical-sanitary and pharmaceutical 
assistance management characteristics.
RESULTS: We analyzed 987 lawsuits, which requested 1,517 medications. Of these, 60.7% 
were not part of the National List of Essential Medicines, and, in 75% of the cases, there was a 
therapeutic alternative in the Brazilian Unified Health System. In 13.6% of the actions, at least 
one drug was prescribed for off-label use. Prescribers of philanthropic and private services often 
request medicines not covered by the pharmaceutical care policy. Even judicialized drugs that 
are part of the national list are constantly requested for non-standard indications.
CONCLUSIONS: Court decisions for the supply of medicines violate health rules and make 
it difficult to manage pharmaceutical assistance, which may weaken the implementation of 
these policies.
DESCRIPTORS:  Access to Essential Medicines and Health Technologies.  Health’s 
Judicialization,  legislation & jurisprudence. National Policy of Pharmaceutical Assistance. 
Right to Health.
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INTRODUCTION
Medicines are fundamental to health systems, and their use involves a conflicting social context: 
they are an essential good, but also a product with high market value. Given their importance, 
in many countries, access to essential medicines is an integral part of human rights1.
In Brazil, integral therapeutic care, including pharmaceutical assistance, is a right 
guaranteed to all citizens, being part of the list of services provided by the Unified Health 
System (SUS). After implementing the SUS as public health policy in Brazil, pharmaceutical 
assistance (PA) was formally included by ordinance GM/MS no. 3.916/1998, which instituted 
the Política Nacional de Medicamentos (PNM – National Medicine Policy), aiming to ensure 
universal access to safe, effective, quality medicines at the lowest possible price for all. 
Subsequently, PA was ratified as a public health policy by resolution no. 338 of 2004 of the 
Conselho Nacional de Saúde (CNS – National Health Council), which instituted the Política 
Nacional de Assistência Farmacêutica (PNAF – National Pharmaceutical Assistance Policy)2.
Among the priority guidelines of PNM, the adoption of Relação Nacional de Medicamentos 
Essenciais (Rename – National List of Essential Medicines), permanently revised, is considered 
a guiding point of medicine policy, to guide administration and rational use. Currently, the 
PA in SUS is organized in three components: basic, composed of medicines to treat the most 
prevalent diseases in primary health care; strategic, for medicines for endemics and diseases of 
epidemiological importance; and specialized, for medications with use described in the Protocolos 
Clínicos e Diretrizes Terapêuticas (PCDT – Clinical Protocols and Therapeutic Guidelines)3
Despite the advances observed after more than 20 years of PNM, new challenges have been 
imposed, among them the phenomenon of judicialization in access to medicines. Protected by 
the constitutional right to health, individuals resort to the Court to have access to medications, 
both those already incorporated into SUS4 and those that are not yet available by it5.
Some authors also state that judicialization is a strategy of pressure to incorporate new 
technologies6,7. Therefore, to ensure health, and thus the dignity of the human person, 
sanitary aspects that involve lawsuits for the supply of medicine deserve attention8.
In this context, the objective of this study was to analyze whether the individual lawsuits 
requesting medicines, filed against the state of Rio Grande do Norte, agree with the medical-
sanitary and pharmaceutical assistance administration criteria established by public 
policies of access to medicines in force in the country.
METHODS
Study Design
This is a descriptive and retrospective study whose unit of analysis was the individual 
lawsuit requesting medicines filed by the citizen against the state of Rio Grande do Norte.
The research included processes pending in the first instance, with distribution date between 
January 2013 and December 2017. The study period has as initial milestone the year from 
which the Secretaria de Estado de Saúde Pública do Rio Grande do Norte (Sesap/RN – State 
Department of Public Health of Rio Grande do Norte) began to systematically organize 
lawsuits requesting medications, with 2017 as the final year, thus analyzing a five-year 
period. We excluded from the database lawsuits that were in legal confidentiality, public 
civil actions and those that did not request medicines.
Variables
The study variables were selected from the Manual de Indicadores de Avaliação e 
Monitoramento das Demandas Judiciais por Medicamentos9. To meet the objective of the 
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study, we chose variables from lawsuits that evaluated medical-sanitary and pharmaceutical 
assistance management characteristics, which were: name of the drug(s) requested, presence 
of the drug in Rename, proportion of drugs demanded by pharmaceutical assistance 
financing block, proportion of drugs demanded with therapeutic alternative in SUS, 
proportion of lawsuits with at least one medication prescribed for off-label use, origin of 
the medical prescription (public, private or philanthropic service), agreement of the drugs 
demanded and present in Rename with the PCDT.
Data Collection and Classification
Data regarding lawsuits were obtained in the Judicial Demands Center of the Unidade 
Central de Agentes Terapêuticos (Unicat – Central Unit of Therapeutic Agents). This database 
provided to the researchers the number of the lawsuit, the name of the author of the action 
and the medicine requested. From this information, we consulted the case files available in 
the procedural management systems of the Tribunal de Justiça do Rio Grande do Norte (TJRN 
– Court of Justice of Rio Grande do Norte) and the Justiça Federal no Rio Grande do Norte 
(JFRN – Federal Court of Rio Grande do Norte) in order to collect detailed information on 
the lawsuits and build a database with the variables of interest. For this purpose, a semi-
structured questionnaire was constructed, using the Excel software (Microsoft, 2013).
After collection, we reviewed the data and classified the medicines using the Anatomical 
Therapeutic Chemical System (ATC) The presence of the medicine in official public lists was 
verified by consulting the Rename 2014, which was in force for most of the study period. 
The same relation was consulted to assess the presence of therapeutic alternative in SUS, 
considering that a drug from the same pharmacological subgroup by ATC classification 
for the same therapeutic indication is interchangeable.
Off-label use was determined after analyzing the diagnostic indication in the records of 
the lawsuit, and consulting the medicine leaflet, using as source the National Sanitary 
Surveillance Agency (ANVISA)a. We considered off-label a medicine prescribed for an 
indication other than that approved by health autorities9. Medicines judicially demanded 
that were part of the Componente Especializado da Assistência Farmacêutica (CEAF – 
Specialized Component of Pharmaceutical Care) were analyzed considering if they agreed 
with therapeutic indication with the PCDT in force. Figure 1 summarizes data collection 
and analysis process.
Statistical Analyses
For data analysis, the SPSS software was used (version 20). Continuous variables were 
categorized and showed as absolute and relative frequency. To compare categorical variables, 
we used the Pearson chi-square test, with a 5% significance level.
Ethical Considerations
This study is the result of a research project entitled Análise das demandas judiciais por 
medicamentos no Rio Grande do Norte, which was submitted and approved by the Research 
Ethics Committee of the University Hospital Onofre Lopes, with opinion no. 2.404.850.
Unicat: Unidade Central de Agentes Terapêuticos (Central Unit of Therapeutic Agents); ATC: Anatomical Therapeutic Chemical system; Rename: Relação 
Nacional de Medicamentos Essenciais (National List of Essential Medicines); SUS: Unified Health System; PCDT: Protocolos Clínicos e Diretrizes 
Terapêuticas (Clinical Protocols and Therapeutic Guidelines).
Figure. Flowchart of data collection and classification.
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RESULTS
We identified 1,635 lawsuits, of which 987 fell within the inclusion criteria and were analyzed 
in the investigation. A total of 1,517 medicines were requested, being 328 different items, 
with an average request of 1.55 (standard deviation of 1.40) drugs per legal action.
The analyses of medical-sanitary and pharmaceutical assistance management variables 
showed that most of the medicines judicially requested are not yet incorporated into SUS. 
Of those which were requested and included in the Rename, the ones belonging to CEAF 
were most frequent. We observed that there is a high proportion of medicines not included in 
the Rename with therapeutic alternative in SUS. Of the 987 analyzed lawsuits, we identified 
that, in 13.6%, there was at least one drug prescribed for an indication not described in the 
leaflet, that is, an off-label use (Table 1).
When evaluating the relation between type of drug requested according to the ATC classification 
and its inclusion in Rename, we observed a significant association (p<0.001), showing that the 
proportion of requested medicines included in Rename varies according to the therapeutic 
subgroup. Drugs that act on the respiratory, musculoskeletal and digestive systems and 
metabolism, as well as antineoplastic agents and immunomodulators, have higher proportion 
not included in Rename, while medications that act in the cardiovascular and nervous systems 
and systemic hormonal preparations have a higher proportion of incorporation in the national 
list (Table 2). When analyzing the association between origin of the prescription and inclusion 
in Rename, we noticed that prescriptions from philanthropic and private services request more 
medicines outside Rename than those from public services (Table 2).
In Table 3, the 10 most frequently requested drugs are listed according to their inclusion in 
Rename, therapeutic alternative, and, in the case of those that are included in official lists, 
agreement with the current PCDT. Of the drugs not incorporated to the pharmaceutical 
care policy, insulin glargine, tiotropium bromide, fast-acting insulin analogues (lispro and 
aspart) and osteoporosis treatment drugs (teriparatide and denosumab) led the requests; 
there was no alternative in SUS for only 2 of the 10 most requested medicines (bevacizumab 
for use as an antineoplastic agent and for intravitreal use).
Finally, of the requested drugs contemplated in the policy, Somatropin was the most 
requested, with the indication of the request agreeing 100% with the clinical guidelines 
of SUS, a situation similar to requests of azatioprine and mesalazine. The other drugs, 
although included in the policy, were frequently requested for non-standard indications 
in the PCDT, with mycophenolate mofetil standing out, which was judicially requested in 
18 actions, none of them for the standardized indication by SUS (Table 3).
Table 1. Medical-sanitary and pharmaceutical assistance management characteristics of lawsuits 
requesting medicines. Rio Grande do Norte, 2013–2017.
n %
Presence in Rename (n = 1,517)
No 922 60.7
Yes 596 39.3




Proportion of drugs demanded outside Rename with alternative in SUS (n = 922) 692 75.0
Proportion of off-label use (n = 987) 134 13.6
Rename: Relação Nacional de Medicamentos Essenciais (National List of Essential Medicines); CBAF: 
Componente Básico da Assistência Farmacêutica (Basic Component of Pharmaceutical Assistance); CEAF: 
Componente Especializado da Assistência Farmacêutica (Specialized Component of Pharmaceutical Assistance); 
CESAF: Componente Estratégico da Assistência Farmacêutica (Strategic Component of Pharmaceutical 
Assistance); SUS: Unified Health System
Source: Research data, 2019.
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DISCUSSION
In this study, we observed that most of the drugs requested from Court are not incorporated 
into SUS, although there is a therapeutic alternative available. There is an association between 
the claimed class of drugs and its presence in Rename, with a low adherence of prescribers 
to drugs included in the components of pharmaceutical assistance and a predominance of 
prescribed drugs not included in Rename by doctors linked to philanthropic and private 
institutions. Even in the case of drugs in the list, we observed prescriptions that disagreed 
with the indication provided in PCDT.
Empirical studies that evaluated the type of drug required show that there is no national 
standard. There are investigations with predominance of requests for medicines from 
Table 2. Classification of medicines and origin of medical prescription of drugs requested in lawsuits 





A- Digestive system and metabolism 247 (80.7%) 59 (19.3%) 306
B- Blood and blood-forming organs 101 (72.7%) 38 (27.3%) 139
C- Cardiovascular system 90 (45.5%) 108 (54.5%) 198
H- Systemic hormonal preparations 54 (38.3%) 87 (61.7%) 141
L- Antineoplastic and immunomodulating agents 185 (57.3%) 138 (42.7%) 323
M- Musculoskeletal system 41 (80.4%) 10 (19.6%) 51
N- Nervous system 79 (45.4%) 95 (54.6%) 174
R- Respiratory system 82 (88.2%) 11 (11.8%) 93
Others 43 (46.2%) 50 (53.8%) 93
Total 922 (60.7%) 596 (39.1%) 1,517
Origin of medical prescriptionb
Private services 224 (59.6%) 152 (40.4%) 376
Public services 123 (53.2%) 108 (46.7%) 231
Philanthropic services 61 (75.3%) 20 (24.7%) 81
Total 408 (59.3%) 208 (30.2%) 688
Rename: Relação Nacional de Medicamentos Essenciais (National List of Essential Medicines); ATC: Anatomical 
Therapeutic Chemical System.
a Chi-square test: p < 0.001.
b Chi-square test: p < 0.002.
Source: Research data, 2019.
Table 3. Most requested drugs in lawsuits according to the inclusion in Rename, therapeutic alternative in SUS and agreement with PCDT. 
Rio Grande do Norte, 2013–2017.
Drugs not included in 




Medicines included in 
Rename (n = 596)
n % Agreement with PCDT (%)
Insulin glargine 74 8.0 Y Somatropin 53 8.9 100.0
Tiotropium bromide 58 6.3 Y Rituximab 25 4.2 8.0
Enoxaparin 57 6.2 Y Azathioprine 21 3.7 90.5
Insulin lispro 32 3.5 Y Mycophenolate mofetil 18 3.1 0.0
Teriparatide 30 3.3 Y Clopidogrel 16 2.7 12.5
Bevacizumab (intravitreal) 25 2.7 N Infliximab 14 2.3 21.4
Insulin aspart 24 2.6 Y Acetylsalicylic acid 13 2.2 100.0
Bevacizumab 21 2.3 N Goserreline 13 2.2 23.1
Denosumab 21 2.3 Y Deferasirox 12 2.0 25.0
Rivaroxabane 19 2.1 Y Mesalazine 12 2.0 83.3
Rename: Relação Nacional de Medicamentos Essenciais (National List of Essential Medicines); SUS: Unified Health System; PCDT: Protocolos Clínicos e 
Diretrizes Terapêuticas (Clinical Protocols and Therapeutic Guidelines); Y: yes; N: no
Source: Research data, 2019.
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public policy4,5,10,11; however, most of the empirical data are similar to ours, with most of 
the judicialized drugs not included in Rename12–16.
A hypothesis that justifies this heterogeneous panorama is that health judicialization show 
relevant regional differences that are reflected in health care and justice systems. Therefore, 
in states in which the largest number of lawsuits is for medicines included in the national 
policy, there may be failures in the management of pharmaceutical care, while in those in 
which requests are mainly for drugs outside the official lists, the policy works well, and only 
what is not provided to the citizen because it is still not available in SUS reaches the court17.
Another hypothesis for the judicialization of medicines not yet available in SUS is that 
there is a delay in the incorporation of technologies, as well as a lack of technical criteria 
and transparency in the incorporation process18. However, an analysis that compared the 
Rename editions published from 2000 to 2014 observed an increased number of medicines 
in the editions published after 2012, without the expected decrease in judicialization and 
in the pressure for the technological incorporation of innovative products, which, on the 
contrary, have increased in recent years19. Rename suffered alterations in its elaboration 
process, moving from a list based on the concept of essentiality in the 1998 to 2010 editions, 
to a positive relation of drugs covered by the SUS from 2012, with the publication of law 
no.12.401/2011 and decree 7.508/2011, which regulated the concept of integrality in the SUS 
and brought changes to the technology incorporation process7,19.
Our data showed that most of the claimed drugs outside Rename have a therapeutic 
alternative in SUS. For example, one of the most requested drugs was tiotropium bromide, 
indicated for treating asthma or chronic obstructive pulmonary disease (COPD), which has 
the association of formoterol and budesonide as therapeutic alternative in SUS, belonging 
to CEAF. Previous studies that evaluated the proportion of requested drugs that have 
therapeutic alternative in SUS showed prevalence ranging from 41.7% to 96.0%. These data 
show that the SUS administration is not completely omitted, since it provides treatment 
options for the diseases that justify the judicial requests20.
Some classes of medicines are preferred targets of requests for non-incorporated drugs, 
although they do not treat the most prevalent diseases in the population. An analysis of 
the applications for incorporation to Rename from 2012 to 2016 showed that medications 
in the anti-infectious classes for systemic use to treat HIV/AIDS and hepatitis C, and the 
ones indicated for musculoskeletal disorders, neoplams, mental and behavioral disorders, 
and respiratory diseases accounted for 64.5% of the incorporated drugs. These data show 
that there is an increase in the availability of medicines by SUS, including classes that are 
usually demanded judicially, which corroborates our findings21.
By abandoning the concept of essentiality, based on the epidemiological demands of the 
population, Rename has become more susceptible to political and social pressures to 
incorporate new technologies, which do not always show therapeutic superiority. This is a 
worrying fact that opposes the guidelines established by the PNM, since it compromises 
PA management and the adherence of medical professionals to the SUS lists18,19.
Another priority guideline established by PNM is rational use and safety of medicines, being 
the off-label prescription an indication of the lack of efficacy and safety in use. Our data 
show that the most prescribed medicine for off-label use was intravitreal bevacizumab, 
with 35 requests for various clinical indications, with diabetic retinopathy, glaucoma and 
age-related macular degeneration (AMD) standing out.
Bevacizumab is registered in ANVISA with indication for the treatment of cancer, but 
it has been used off-label for AMD. In view of intense judicialization and the lack of 
therapeutic option in SUS, in 2016, ANVISA authorized its exceptional and temporary use 
for three years for the treatment of AMD, according to rules established in a protocol that 
provides intravitreal use only for AMD (code H35.3 of the 10th revision of the International 
Classification of Diseases)22. However, we found that, of the 35 judicial requests for this drug, 
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only five had this indication, evidencing that the SUS has sought to fill gaps in its policies, 
however, new uses and indications end up continuously fueling judicialization.
One of the protagonists of health judicialization are medical professionals. Studies on the topic 
have pointed out the relations between prescribers, pharmaceutical industry and lawyers who 
act in a coordinated manner, generating judicial demand for medicines and, thus, pressing 
their incorporation6,23,24. In our study, we observed that doctors from philanthropic institutions 
and private health services prescribe more drugs not included in Rename than doctors from 
SUS, despite the fact that all prescribers predominantly request non-standard drugs.
This shows that the authors from private and philanthropic services resort to the Court to 
have access, by SUS, mainly to medicines not incorporated by the system. It is noteworthy 
that, in our sample, the main philanthropic service that generated lawsuits was an 
oncological hospital affiliated to SUS and that, therefore, already receives funding through 
Procedimento de Alta Complexidade em Oncologia (Authorization of High Complexity 
Procedure in Oncology). Empirical studies show that the main judicial criterion for a 
favorable decision to the litigant is the evidence shown by the plaintiff, usually based on a 
medical report or prescription25,26.
Therefore, caution is necessary, above all, in relation to the prescription of medicines non 
included in the official lists of drugs or in non-compliance with officially established clinical 
protocols. It is necessary to question whether the intended treatment has scientific evidence 
and if it is possible to replace it with a therapeutic alternative available in the public health 
network, because, otherwise, the harmful effects of fragmented individual decisions will 
undermine public policies, which make priority choices for the allocation of scarce resources. 
Ignoring public policies ultimately strengthens discriminatory situations and unsustainable 
medical technologies from the scientific point of view26,27.
When analyzing the most requested drugs not available in SUS, we see the predominance of 
requests for both short and long-acting insulin analogues. Empirical studies carried out in 
other states, such as São Paulo and Bahia, also found insulin analogue as the most requested 
drugs not included in Rename12,28,29. Of the 10 most requested drugs, only bevacizumab for 
intravitreal use and for cancer treatment does not have an alternative available in the SUS.
It is also interesting to observe the dynamics between judicialization and incorporation 
of technologies into SUS. Five of the ten drugs most judicially requested to the state in the 
study period, including some with an opinion contrary to the incorporation into the SUS, 
were recently incorporated, between 2016 and 2019. The case of insulin analogue is didactic 
for this relation between judicialization and incorporation, since, after two negative stances 
on incorporation in 2014, the Comissão Nacional de Incorporação de Tecnologias no SUS 
(Conitec – National Commission for Incorporation of Technologies in SUS), recommended 
the incorporation of fast-acting insulins by SUS for the treatment of type 1 diabetes mellitus 
(DM1) in 2017, and, in March 2019, a new, favorable opinion was issued in favor of long-acting 
insulin analogue for DM1, even without new scientific evidence of superiority. The opinion 
described the “lawsuits of these drugs” as an issue to be analyzed22.
Other drugs targeted by lawsuits recently incorporated were enoxaparin for the prevention 
of thrombophilia in pregnant women and the already described intravitreal bevacizumab, 
with exceptional use approved for three years. The others were evaluated by Conitec, which 
opposed the incorporation since they do not show a superior efficacy to technologies already 
available in SUS. Only denosumab has no record of evaluation by Conitec to date22.
Although most of the drugs judicially requested are not included in Rename, a considerable 
percentage of these medicines already incorporated by the policy was also requested, most 
being from CEAF. The Judiciary search for medicines of this component may mean failures 
in its management, as well as attempts to circumvent the legally established criteria. When 
analyzing the agreement between the requested drug and the clinical indication described in 
the medical report with the current PDCT, we observed possible failures in the management 
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of pharmaceutical care in the request for the drugs somatropin, azathioprine, acetylsalicylic 
acid and mesalazine, since the vast majority of requests agreed with protocols. For the 
other drugs requested, the highest prevalence was for clinical indications non-standard 
in official protocols, most for off-label uses. Mycophenolate mofetil stands out, for which 
none of the clinical indications described in the lawsuits agreed with the PCDT, and in 12 of 
the 18 solicitations, it was prescribed for off-label use. We observed that lawsuits usually 
lack technical evidentiary criteria, being instructed with medical report and prescription, 
rarely with the presence of examinations, and have made the judicial route a faster way with 
higher success rates in obtaining the medicine requested, since these documents would be 
insufficient in many cases to ensure access by the SUS8,26.
This study has limitations, since we portray a local reality; however, considering the lack of 
multicenter studies and of a national panorama of judicialization in access to medicines, we 
considered that local research is necessary to deepen the knowledge on the phenomenon. In 
addition, the study was carried out from data consulted in procedural documents available 
in the court management systems, by the information obtained in the Sesap/RN, being a 
convenience sample, since it there is no specific management system for these lawsuits.
From the data analysis, it may be concluded that, in many cases, the Court generates 
breaking points in the existing public policy, going over criteria that were elaborated to 
safeguard the health of the population and a more efficient management of public resources. 
In this sense, in order to ensure the right to health, sanitary rules are violated, and the 
management of pharmaceutical assistance is hampered. We emphasize that the supply of 
a drug does not necessarily translate into a guarantee of the health of the individual. After 
the judicial decision, the Court or the health services do not officially monitor or verify the 
conditions of use, the evolution or the achievement of the therapeutic goals intended by the 
prescriber; thus, the sanitary outcomes for the health of the patients is unknown. Therefore, 
new investigations should be directed towards this analysis.
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